

Intercept Pharmaceuticals Inc (ICPT) - Financial and Strategic SWOT Analysis Review

https://marketpublishers.com/r/IA061DC4B11EN.html

Date: March 2021

Pages: 52

Price: US\$ 125.00 (Single User License)

ID: IA061DC4B11EN

Abstracts

Intercept Pharmaceuticals Inc (ICPT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.



Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Intercept Pharmaceuticals Inc (Intercept) is a biopharmaceutical company that researches, develops, and commercializes treatments for non-viral, progressive liver diseases. It develops products using proprietary bile acid chemistry. The company's lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor. The company is advancing OCA for the treatment of various other liver diseases. The company harnesses its proprietary bile acid chemistry to develop innovative drugs. It is also advancing INT-787, an FXR agonist with anti-inflammatory and anti-fibrotic effects that can be indicated for broad range of diseases. The company has operations in the US, Europe and Canada. Intercept is headquartered in New York, the US.

Intercept Pharmaceuticals Inc Key Recent Developments

Mar 10,2021: Intercept Announces Departure of Chief Financial Officer

Feb 25,2021: Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results, Issues 2021 Financial Guidance and Provides Business Update

Feb 23,2021: Intercept appoints Dagmar Rosa-Bjorkeson to its Board of Directors

Feb 17,2021: Intercept Appoints Linda Richardson as Chief Commercial Officer



Feb 11,2021: Intercept to Announce Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.



Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Contents

SECTION 1 - ABOUT THE COMPANY

Intercept Pharmaceuticals Inc - Key Facts

Intercept Pharmaceuticals Inc - Key Employees

Intercept Pharmaceuticals Inc - Key Employee Biographies

Intercept Pharmaceuticals Inc - Major Products and Services

Intercept Pharmaceuticals Inc - History

Intercept Pharmaceuticals Inc - Company Statement

Intercept Pharmaceuticals Inc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview

Intercept Pharmaceuticals Inc - Business Description

Product Category: Licensing Revenue

Performance

Product Category: Net product revenue

Performance R&D Overview

Intercept Pharmaceuticals Inc - Corporate Strategy

Intercept Pharmaceuticals Inc - SWOT Analysis

SWOT Analysis - Overview

Intercept Pharmaceuticals Inc - Strengths

Intercept Pharmaceuticals Inc - Weaknesses

Intercept Pharmaceuticals Inc - Opportunities

Intercept Pharmaceuticals Inc - Threats

Intercept Pharmaceuticals Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios



Financial Ratios - Ratio Charts

SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Intercept Pharmaceuticals Inc, Recent Deals Summary

SECTION 5 – COMPANY'S RECENT DEVELOPMENTS

Mar 10, 2021: Intercept Announces Departure of Chief Financial Officer

Feb 25, 2021: Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2020

Financial Results, Issues 2021 Financial Guidance and Provides Business Update

Feb 23, 2021: Intercept appoints Dagmar Rosa-Bjorkeson to its Board of Directors

Feb 17, 2021: Intercept Appoints Linda Richardson as Chief Commercial Officer

Feb 11, 2021: Intercept to Announce Fourth Quarter and Full Year 2020 Financial

Results on February 25, 2021

Jan 11, 2021: Intercept appoints Jared M. Freedberg as General Counsel and Secretary

Dec 10, 2020: Intercept Pharmaceuticals announces leadership transition

Nov 09, 2020: Intercept Pharmaceuticals reports third quarter 2020 financial results,

announces updates to financial guidance and provides business update

Aug 10, 2020: Intercept Pharmaceuticals reports second guarter 2020 financial results,

announces updates to financial guidance and provides business update

May 11, 2020: Intercept Pharmaceuticals reports first quarter 2020 financial results, and

provides business update

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer



List Of Tables

LIST OF TABLES

Intercept Pharmaceuticals Inc, Key Facts

Intercept Pharmaceuticals Inc, Key Employees

Intercept Pharmaceuticals Inc, Key Employee Biographies

Intercept Pharmaceuticals Inc, Major Products and Services

Intercept Pharmaceuticals Inc, History

Intercept Pharmaceuticals Inc, Other Locations

Intercept Pharmaceuticals Inc, Subsidiaries

Intercept Pharmaceuticals Inc, Key Competitors

Intercept Pharmaceuticals Inc, Ratios based on current share price

Intercept Pharmaceuticals Inc, Annual Ratios

Intercept Pharmaceuticals Inc, Annual Ratios (Cont...1)

Intercept Pharmaceuticals Inc, Interim Ratios

Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to

YTD 2021

Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to

YTD 2021

Intercept Pharmaceuticals Inc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios



List Of Figures

LIST OF FIGURES

Intercept Pharmaceuticals Inc, Performance Chart (2016 - 2020)

Intercept Pharmaceuticals Inc, Ratio Charts

Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021



I would like to order

Product name: Intercept Pharmaceuticals Inc (ICPT) - Financial and Strategic SWOT Analysis Review

Product link: https://marketpublishers.com/r/IA061DC4B11EN.html

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/IA061DC4B11EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970